Your browser is no longer supported. Please, upgrade your browser.
NVO Novo Nordisk A/S monthly Stock Chart
Novo Nordisk A/S
Index- P/E25.59 EPS (ttm)2.77 Insider Own26.40% Shs Outstand2.34B Perf Week-3.86%
Market Cap127.46B Forward P/E22.92 EPS next Y3.09 Insider Trans0.00% Shs Float1.13B Perf Month1.93%
Income6.52B PEG2.84 EPS next Q0.71 Inst Own8.30% Short Float0.37% Perf Quarter3.59%
Sales19.91B P/S6.40 EPS this Y2.80% Inst Trans-0.03% Short Ratio4.42 Perf Half Y10.42%
Book/sh4.04 P/B17.52 EPS next Y8.69% ROA32.30% Target Price72.35 Perf Year34.77%
Cash/sh2.17 P/C32.57 EPS next 5Y9.00% ROE73.70% 52W Range49.24 - 73.81 Perf YTD22.29%
Dividend1.04 P/FCF27.53 EPS past 5Y10.20% ROI69.10% 52W High-4.11% Beta0.41
Dividend %1.47% Quick Ratio0.80 Sales past 5Y6.60% Gross Margin83.70% 52W Low43.74% ATR1.31
Employees43526 Current Ratio1.10 Sales Q/Q-0.10% Oper. Margin43.40% RSI (14)54.44 Volatility1.46% 1.44%
OptionableYes Debt/Eq0.07 EPS Q/Q12.90% Profit Margin32.70% Rel Volume0.83 Prev Close71.02
ShortableYes LT Debt/Eq0.05 EarningsAug 06 BMO Payout294.40% Avg Volume943.80K Price70.78
Recom3.00 SMA200.91% SMA504.25% SMA20010.86% Volume782,445 Change-0.34%
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Sep-17-19Upgrade Citigroup Neutral → Buy
Aug-30-19Downgrade Jefferies Hold → Underperform
Jun-20-19Downgrade Deutsche Bank Buy → Hold
Jun-11-19Upgrade Barclays Underweight → Equal Weight
Apr-29-19Upgrade Credit Suisse Neutral → Outperform
Jan-29-19Initiated Exane BNP Paribas Outperform
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17Upgrade BofA/Merrill Underperform → Neutral
Oct-19-20 06:50PM  
Oct-13-20 03:31PM  
Oct-12-20 04:14AM  
Oct-11-20 01:52PM  
Oct-09-20 01:41PM  
Oct-08-20 12:40PM  
Oct-05-20 08:35AM  
Sep-29-20 06:47PM  
Sep-28-20 08:20AM  
Sep-24-20 04:30AM  
Sep-22-20 08:46AM  
Sep-21-20 02:03PM  
Sep-18-20 03:14PM  
Sep-16-20 10:19PM  
Sep-14-20 04:59AM  
Sep-07-20 08:02AM  
Aug-31-20 09:03AM  
Aug-26-20 03:38PM  
Aug-24-20 09:24AM  
Aug-17-20 08:59AM  
Aug-14-20 09:18AM  
Aug-13-20 05:11AM  
Aug-11-20 10:42AM  
Aug-07-20 12:24PM  
Aug-06-20 11:34AM  
Aug-05-20 07:05AM  
Jul-30-20 07:32PM  
Jul-28-20 05:35PM  
Jul-20-20 05:49AM  
Jul-17-20 07:13PM  
Jul-16-20 09:28AM  
Jul-13-20 10:27AM  
Jul-09-20 03:57PM  
Jul-07-20 06:48PM  
Jul-06-20 04:03PM  
Jun-30-20 12:46PM  
Jun-22-20 09:39AM  
Jun-19-20 12:49PM  
Jun-17-20 01:06PM  
Jun-15-20 01:46PM  
Jun-12-20 09:48AM  
Jun-11-20 10:15PM  
Jun-01-20 09:53AM  
May-29-20 12:39PM  
May-27-20 08:13AM  
May-08-20 11:04AM  
May-07-20 11:18AM  
May-06-20 09:00PM  
Apr-30-20 11:40AM  
Apr-29-20 09:27AM  
Apr-28-20 12:33PM  
Apr-26-20 03:11AM  
Apr-16-20 06:50PM  
Apr-14-20 02:43PM  
Apr-09-20 09:03AM  
Apr-07-20 06:33AM  
Apr-06-20 06:26PM  
Apr-05-20 09:14PM  
Apr-02-20 01:20PM  
Apr-01-20 11:40AM  
Mar-31-20 12:43PM  
Mar-23-20 09:07AM  
Mar-20-20 12:23PM  
Mar-19-20 06:51PM  
Mar-12-20 08:41PM  
Mar-11-20 08:45AM  
Mar-10-20 05:26AM  
Mar-04-20 12:51PM  
Feb-20-20 05:10PM  
Feb-13-20 11:40AM  
Feb-12-20 10:29AM  
Feb-09-20 02:21AM  
Feb-07-20 10:24AM  
Feb-06-20 12:29PM  
Feb-05-20 04:11PM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.